{"id":793738,"date":"2024-12-10T08:14:13","date_gmt":"2024-12-10T13:14:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/"},"modified":"2024-12-10T08:14:13","modified_gmt":"2024-12-10T13:14:13","slug":"nextcure-announces-acceptance-of-ind-application-for-lncb74","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/","title":{"rendered":"NextCure Announces Acceptance of IND Application for LNCB74"},"content":{"rendered":"<h2>\nLNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BELTSVILLE, Md., Dec.  10, 2024  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GF64z2gWauHW_8pMOrKz0wApJONBXvpitjJv3kglnDyxU6UCljcjroJfzKyTaweij53fko3cpmAVt1_VSZScdw==\" rel=\"nofollow\" target=\"_blank\">NextCure, Inc.<\/a> (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers.<\/p>\n<p>\u201cAcceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program,\u201d said Michael Richman, NextCure\u2019s president and CEO. \u201cThe IND application leverages LNCB74 preclinical data that highlights the differentiation of our B7-H4 ADC from other ADCs targeting B7-H4. We believe LNCB74 has the potential to transform treatment for patients and we look forward to advancing LNCB74 into clinical development.\u201d<\/p>\n<p>An IND is a request submitted to the regulatory authorities seeking permission to test a new drug or therapeutic substance in humans. The IND includes detailed information about the drug, its composition, pharmacology, toxicology, data from preclinical studies, proposed clinical trial protocols, and information on manufacturing and quality control. With the IND application acceptance now complete, NextCure can proceed with the Phase I trial.<\/p>\n<p>LNCB74 is being developed in partnership with LigaChem Biosciences, Inc. as part of a collaboration and co-development agreement.<\/p>\n<p>\n        <strong>About NextCure, Inc.<\/strong>\n      <\/p>\n<p>NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GKBOtmndHhSHomEcSJuhVFixrJVN53M4PytI6R4lEkgJYd1OjeytlC9BDZvMbjkuC7NvsILlOKd9m8N46A3rrA==\" rel=\"nofollow\" target=\"_blank\">www.nextcure.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201caim,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cdue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201chope,\u201d \u201cmay,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cpositioned,\u201d \u201cseek,\u201d \u201ctarget,\u201d \u201ctowards,\u201d \u201cforward,\u201d \u201clater,\u201d \u201cwill,\u201d \u201cwould\u201d and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.<\/p>\n<p>Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure\u2019s limited operating history and not having any products approved for commercial sale; NextCure\u2019s history of significant losses; NextCure\u2019s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; and NextCure\u2019s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure\u2019s actual results are described under the heading \u201cRisk Factors\u201d in NextCure\u2019s most recent Annual Report on Form 10-K and in NextCure\u2019s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.<\/p>\n<p>\n        <strong>Investor Inquiries<br \/><\/strong>Timothy Mayer, Ph.D.<br \/>NextCure, Inc.<br \/>Chief Operating Officer<br \/>(240) 762-6486<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CFkX3iyRVVZl179aZAwXH9RlIsr9dsj6CCesH2XDNZHMrpKHVRxSKvx-ithG4MoIbJClIMt8EQjiGaiVIQMcqg==\" rel=\"nofollow\" target=\"_blank\">IR@nextcure.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTE1NDQwNTQtNzMzOS00NDI2LTgwMjMtNWZiMWY4MzZmM2VkLTExMzc0MDc=\/tiny\/NextCure.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. \u201cAcceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program,\u201d said Michael Richman, NextCure\u2019s president and CEO. \u201cThe IND application leverages LNCB74 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NextCure Announces Acceptance of IND Application for LNCB74&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793738","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NextCure Announces Acceptance of IND Application for LNCB74 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NextCure Announces Acceptance of IND Application for LNCB74 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. \u201cAcceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program,\u201d said Michael Richman, NextCure\u2019s president and CEO. \u201cThe IND application leverages LNCB74 &hellip; Continue reading &quot;NextCure Announces Acceptance of IND Application for LNCB74&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T13:14:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NextCure Announces Acceptance of IND Application for LNCB74\",\"datePublished\":\"2024-12-10T13:14:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/\"},\"wordCount\":665,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/\",\"name\":\"NextCure Announces Acceptance of IND Application for LNCB74 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=\",\"datePublished\":\"2024-12-10T13:14:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-announces-acceptance-of-ind-application-for-lncb74\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NextCure Announces Acceptance of IND Application for LNCB74\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NextCure Announces Acceptance of IND Application for LNCB74 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/","og_locale":"en_US","og_type":"article","og_title":"NextCure Announces Acceptance of IND Application for LNCB74 - Market Newsdesk","og_description":"LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. \u201cAcceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program,\u201d said Michael Richman, NextCure\u2019s president and CEO. \u201cThe IND application leverages LNCB74 &hellip; Continue reading \"NextCure Announces Acceptance of IND Application for LNCB74\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-10T13:14:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NextCure Announces Acceptance of IND Application for LNCB74","datePublished":"2024-12-10T13:14:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/"},"wordCount":665,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/","name":"NextCure Announces Acceptance of IND Application for LNCB74 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=","datePublished":"2024-12-10T13:14:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjQ2MiM2NjI5MjIwIzIxMjU4MzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-announces-acceptance-of-ind-application-for-lncb74\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NextCure Announces Acceptance of IND Application for LNCB74"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793738"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793738\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}